A Multicenter Phase I Clinical and Pharmacokinetic Study of Oral TAK-593 in Subjects With Nonhematologic Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2010
At a glance
- Drugs TAK 593 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 28 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 05 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.